A new study by researchers at Lund University in Sweden supports the notion that patients with type 2 diabetes should be divided into subgroups and given individualized treatment. The study demonstrates that there are distinct epigenetic differences between different groups of patients with type 2 diabetes. The epigenetic markers are also associated with different risks of developing common complications in type 2 diabetes, such as stroke, heart attack and kidney disease.
Epigenetic markers predict complications in patients with type 2 diabetes
A new study by researchers at Lund University in Sweden supports the notion that patients with type 2 diabetes should be divided into subgroups and given individualized treatment. The study demonstrates that there are distinct epigenetic differences between different groups of patients with type 2 diabetes. The epigenetic markers are also associated with different risks of developing common complications in type 2 diabetes, such as stroke, heart attack and kidney disease.